Shorts

1:03

Chemobrain Vs Dementia: Understanding the Difference

7 months ago

Yesne Alici, MD

In a discussion with CancerNetwork®, Natalia Neparidze, MD, spoke about the importance of minimal residual disease (MRD) as a relevant end point for clinical trials assessing novel therapeutic strategies among patients with multiple myeloma.

0:40

MRD is ‘Exceedingly Helpful’ in Assessing Multiple Myeloma Disease Course

7 months ago

Natalia Neparidze, MD

After the FDA granted priority review to rusfertide as a potential therapeutic option for patients with polycythemia vera, CancerNetwork® spoke with Andrew Kuykendall, MD, about what a potential FDA approval would mean for these patients.

0:45

Rusfertide Approval Would Move Past ‘Archaic’ Polycythemia Vera Standard

7 months ago

Andrew T. Kuykendall, MD

Maha Hussain, MD, MBChB, discussed advantages associated with docetaxel-containing triplet regimens for this patients with metastatic HSPC following a Medical Crossfire session she was a presenter for.

1:22

Triplet Therapy Appears to Be Generally Well Tolerated in Metastatic HSPC

7 months ago

Maha Hussain, MD

Tanya Dorff, MD, discussed findings from her presentation comparing doublet and triplet regimens among patients with hormone-sensitive prostate cancer within a Medical Crossfire session held at the New York GU Cancers Congress.

1:34

Delineating Distinct Advantages With Doublet Therapy in HSPC

7 months ago

Tanya B. Dorff, MD

0:34

Exploring AI Use in Breast Radiation Oncology

7 months ago

Molly Ingersoll, PhD, discussed the background behind an analysis, which assessed biological differences underlying sex- and gender-based disparities in bladder cancer outcomes.

0:40

Highlighting Sex-Based Disparities in Bladder Cancer Outcomes

7 months ago

Molly Ingersoll, PhD

In this GU Gemstone, Tanya Barauskas Dorff, MD, spoke with CancerNetwork at NY GU.

0:39

GU Gemstones: Tanya B. Dorff, MD

7 months ago

Tanya B. Dorff, MD

Sympathetic nerves actively signal to cancer-associated fibroblasts within the pancreatic tumor microenvironment, inducing a state that promotes tumor aggression.

0:57

Denervation Shows Different Pancreatic Tumor Reductions Across Sexes

7 months ago

Sebnem Ece Eksi, PhD

0:43

Is Proton Therapy Clinically Effective in Breast Cancer?

7 months ago

Chirag Shah, MD

0:44

MajesTEC-3 Trial Shows ‘Remarkable’ Outcomes in R/R Multiple Myeloma

7 months ago

Rajshekhar Chakraborty, MD

During a visit to Columbia University Herbert Comprehensive Cancer Center, CancerNetwork® spoke with Nicole Lamanna, MD, about the implications of the phase 3 AMPLIFY trial (NCT03836261) showing improved efficacy with acalabrutinib (Calquence) plus venetoclax (Venclexta) vs standard of care among patients with chronic lymphocytic leukemia (CLL).

0:31

AMPLIFY Trial Affirms Shift Away From Chemoimmunotherapy in CLL

7 months ago

Nicole Lamanna, MD

Sahil Doshi, MD, discussed the potential for dose reduction strategies with ipilimumab and nivolumab for the treatment of patients with advanced clear cell renal cell carcinoma.

1:14

Considering Reduced Dose Immunotherapy for Frail Metastatic ccRCC Groups

7 months ago

Sahil D. Doshi, MD

In a visit to Columbia University Herbert Irving Cancer Research Center, CancerNetwork® spoke with Brian Henick, MD, about potential adverse effects that may arise with the use of prophylactic steroids for patients who undergo immunotherapy for lung cancer and other diseases.

0:53

Addressing Steroid-Related Toxicities During Immunotherapy for Lung Cancer

7 months ago

Brian Henick, MD

In a recent visit to Columbia University Irving Cancer Research Center, expert researchers and clinicians shared insights on critical therapeutic developments across their respective disciplines.

0:50

Key Advances Across Oncology Research and Care at Columbia University

7 months ago

Russ Conroy

CancerNetwork® spoke with Marc Lehrer Greenwald, MD, about the rising incidence of colorectal cancer among younger patients.

1:09

How a Short Exam Identified a Colorectal Cancer in a Patient in Their 40s

7 months ago

Marc Lehrer Greenwald, MD

In a discussion with CancerNetwork®, Zhaohui Liao Arter, MD, spoke about updated analysis findings from the phase 2 eNRGy trial (NCT02912949) assessing zenocutuzumab-zbco (Bizengri) beyond initial disease progression among patients with NRG1 fusion-positive non–small cell lung cancer.

0:48

Updated Zenocutuzumab Analysis Reveals “Striking” Outcomes in NRG1+ NSCLC

7 months ago

Zhaohui Liao Arter, MD

1:00

The Truth About GLP-1s: Assessing the Risk of Medullary Thyroid Cancer in Humans

8 months ago

Gary Clayman, MD

Marwan G. Fakih, MD, analyzed the current treatment landscape for patients with later-line metastatic colorectal cancer.

1:17

What Are the Best Treatment Options for Patients with Later-Line mCRC?

8 months ago

Marwan G. Fakih, MD

Zin Myint, MD, compared the incidence of AEs among patients with high-risk prostate cancer treated with pembrolizumab and radiotherapy alone vs with olaparib in a phase 2 study.

0:57

Pembro/RT ± Olaparib Shows Similar Safety in High-Risk Prostate Cancer

8 months ago

Zin Myint, MD

In this video, we asked Molly Ingersoll, PhD, a couple of fun, personal questions at ASCO GU.

0:46

GU Gemstones: Molly Ingersoll, PhD

8 months ago

Molly Ingersoll, PhD

$Sagar Lonial, MD, FACP, FASCO, spoke with CancerNetwork® about the FDA’s acceptance of a new drug application for iberdomide plus daratumumab (Darzalex) and dexamethasone for patients with relapsed/refractory multiple myeloma, detailing how a potential approval may impact the treatment paradigm.$

0:46

Iberdomide Might Expand Tool Belt for Finding a Multiple Myeloma Cure

8 months ago

Sagar Lonial, MD, FACP, FASCO